Chronic lymphocytic leukaemia (CLL) is the most common leukaemia among the adults in
the Western World. CLL (and the corresponding nodal entity small lymphocytic lymphoma …

Chronic lymphocytic leukemia is associated with a highly heterogeneous disease course in
terms of clinical outcomes and responses to chemoimmunotherapy. This heterogeneity is …

Background Deletion of chromosome 17p (del [17p]) in patients with chronic lymphocytic
leukaemia confers very poor prognosis when treated with standard chemo-immunotherapy …

We previously reported durable responses and manageable safety of ibrutinib from a 3-year
follow-up of treatment-naïve (TN) older patients (≥ 65 years of age) and relapsed/refractory …

Ibrutinib is an orally administered inhibitor of Bruton tyrosine kinase that antagonizes B-cell
receptor, chemokine, and integrin-mediated signaling. In early-phase studies, ibrutinib …

Background The TP53 gene, encoding tumour suppressor protein p53, is located on the
short arm of chromosome 17 (17p). Patients with 17p deletion (del17p) chronic lymphocytic …

Background Patients with chronic lymphocytic leukaemia (CLL) with TP53 aberrations
respond poorly to first-line chemoimmunotherapy, resulting in early relapse and short …

Purpose To determine the value of minimal residual disease (MRD) assessments, together
with the evaluation of clinical response in chronic lymphocytic leukemia according to the …

During the past 5 years, a number of highly active novel agents, including kinase inhibitors
targeting BTK or PI3Kδ, an antagonist of the antiapoptotic protein BCL-2, and new anti …

Minimal residual disease (MRD) negativity, defined as< 1 chronic lymphocytic leukemia
(CLL) cell detectable per 10 000 leukocytes, has been shown to independently predict for …